SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by University of Leeds
Sponsor:
Information provided by (Responsible Party):
Julia Brown, University of Leeds
ClinicalTrials.gov Identifier:
NCT01295151
First received: February 11, 2011
Last updated: March 5, 2014
Last verified: March 2014
  Purpose

The principal aim of this study is to fill a clear knowledge gap and provide guidance for rheumatologists and reassurance to the patient group on a management challenge faced daily in rheumatology practice. Specifically, it aims to provide robust evidence on the optimal management of patients with established RA that have failed an anti-TNF therapy (the first of the biological therapies to be introduced); in particular, the investigators wish to address whether the currently licensed but non NICE-approved treatment options, TNF-blocking drug or abatacept, are equivalent to the NICE-approved treatment, rituximab. If so, the intention is to broaden treatment options and target these specific therapies to disease sub-groups.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: Etanercept
Drug: Abatacept
Biological: Rituximab
Drug: Adalimumab
Drug: Certolizumab Pegol
Drug: Infliximab
Drug: Golimumab
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug

Resource links provided by NLM:


Further study details as provided by University of Leeds:

Primary Outcome Measures:
  • Change in disease activity. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Change in Disease Activity Score 28 (DAS28) at 6 months (24 weeks).


Secondary Outcome Measures:
  • Reduction in disease activity. [ Time Frame: Baseline and weeks 12, 24, 36 & 48. ] [ Designated as safety issue: No ]
    Proportion of participants who achieve a reduction in DAS28 score of greater than 1.2 from baseline at weeks 12, 24, 36 and 48 with no toxicity.

  • EULAR & ACR Response Scores [ Time Frame: Baseline and weeks 12, 24, 36, 48 ] [ Designated as safety issue: No ]
    EULAR Response Scores and American College of Rheumatology (ACR) Response Scores (evaluated at weeks 12, 24, 36, 48).

  • CDAI (Clinical disease activity index) [ Time Frame: Baseline and weeks 12, 24, 36 & 48. ] [ Designated as safety issue: No ]
    Change in CDAI score from baseline at weeks 12, 24, 36 and 48. Proportion of participants in each CDAI category at weeks 12, 24, 36 & 48.

  • SDAI (Simplified Disease Activity Index) [ Time Frame: Baseline and weeks 12, 24, 36 & 48. ] [ Designated as safety issue: No ]
    Change in SDAI score from baseline at weeks 12, 24, 36 & 48. Proportion of participants in each SDAI category at weeks 12, 24, 36 & 48.

  • ACR/EULAR Boolean remission rates [ Time Frame: Baseline and weeks 12, 24, 36 & 48. ] [ Designated as safety issue: No ]
    Proportion of participants that achieve Boolean remission rate at weeks 12, 24, 36 & 48.

  • Quality of Life Assessments [ Time Frame: Baseline & weeks 12, 24, 36 & 48. ] [ Designated as safety issue: No ]
    RA Quality of Life (RAQoL) score Health Assessment Questionnaire Disability Index (HAQ-DI) (also evaluated at weeks 60, 72, 84 & 96) Hospital Anxiety and Depression Scale (HADS)

  • Safety & Toxicity [ Time Frame: Baseline and weeks 12, 24, 36 & 48. ] [ Designated as safety issue: Yes ]
    Toxicity Adverse Events & Reactions

  • Economic Evaluation [ Time Frame: Baseline & weeks 12, 24, 36 & 48 ] [ Designated as safety issue: No ]
    EuroQol 5-dimensions (EQ-5D) (also evaluated at weeks 60, 72, 84 & 96) Health Utilities Index (also evaluated at weeks 60, 72, 84 & 96) Health and Social Care Use & Expenditure due to Rheumatoid Arthritis (evaluated at weeks 12, 24, 36 & 48) Incremental Cost Effectiveness

  • Imaging (at the discretion of individual sites) [ Time Frame: Baseline and week 48. ] [ Designated as safety issue: No ]
    Change in plain x-ray score of hands and feet (Modified Genant score - evaluated at baseline and week 48) Bone densitometry scan scores (T-scores unilateral neck of femur and lumbar spine - evaluated at baseline and week 48)


Estimated Enrollment: 477
Study Start Date: August 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TNF-blocking drug Drug: Etanercept

Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.

The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.

Drug: Adalimumab

Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.

The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.

Drug: Certolizumab Pegol

Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.

The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique.

Drug: Infliximab

Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.

The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.

Further treatment will be prescribed at the discretion of the treating clinician.

Drug: Golimumab

Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.

Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.

The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice.

Experimental: Abatacept Drug: Abatacept

Abatacept will be administered at a dose determined by body weight:

Body Weight (kg) Dose (mg) < 60kg = 500 mg

> or equal to 60kg and < or equal to 100kg = 750 mg > 100 kg = 1000mg

The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician.

Active Comparator: Rituximab Biological: Rituximab

Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).

In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.

Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Male and female subjects aged ≥18 years at the time of signing the Informed Consent Form.
  2. Patients with a diagnosis of rheumatoid arthritis as per the ACR/EULAR 2010 classification criteria (Appendix 7) confirmed at least 24 weeks prior to the screening visit.
  3. Patients who have failed conventional DMARD therapy as per NICE/BSR Guidelines (49) i.e. failure of at least 2 DMARDS including MTX.
  4. Patients with persistent RA disease activity despite having been treated with a current initial TNFi agent for at least 12 weeks. Active RA defined as*:

    1. Primary non-response: failing to improve DAS28 by > 1.2 (Appendix 6) or failing to achieve DAS28 ≤ 3.2 within the first 12 to 24 weeks of starting the initial TNFi.

      • This may include patients that have shown a reduction in DAS28 of > 1.2 but still demonstrate unacceptably high disease activity in the physician's judgement with evidence of an overall DAS28 of ≥ 3.2 OR

    2. Secondary non-response: defined as inefficacy to first TNFi (having demonstrated prior satisfactory response) as per clinician judgement; with intolerance not the reason for cessation of first TNFi.
  5. MTX dose stable for 4 weeks prior to the screening visit and to be continued for the duration of the study.
  6. Patients on NSAIDs and / or corticosteroids (oral prednisolone not exceeding 10mg daily) who have been on an unchanged regimen for at least 4 weeks prior to the screening visit and are expected to remain on a stable dose until the baseline assessments have been completed.
  7. Provided written informed consent prior to any trial-specific procedures.

Exclusion Criteria

  1. Major surgery (including joint surgery) within 8 weeks prior to the screening visit or planned major surgery within 52 weeks following randomization.
  2. Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter's syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years of age.
  3. Patients receiving doses of prednisolone > 10mg/day within the 4 weeks prior to the screening visit.
  4. Patients receiving intra-articular or intra-muscular steroid injections within 4 weeks prior to the screening visit.
  5. Patients who have previously received more than 1 TNFi drug OR any other biological therapy for the treatment of RA.
  6. Patients unable or unwilling to stop treatment with a prohibited DMARD (i.e synthetic DMARD aside from MTX e.g. oral or injectable gold, chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leflunomide, sulphasalazine) prior to the start of protocol treatment.
  7. Treatment with any investigational drug in the last 12 weeks prior the start of protocol treatment.
  8. Patients with other co-morbidity including acute, severe infections, uncontrolled diabetes, uncontrolled hypertension, unstable ischaemic heart disease, moderate/severe heart failure (Class III/IV of the New York Heart Association (NYHA) functional classification system (79)), active bowel disease, active peptic ulcer disease, recent stroke (within 12 weeks before the screening visit), or any other condition which, in the opinion of the investigator, would put the patient at risk to participate in the study or would make implementation of the protocol difficult.
  9. Patients with any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 12 weeks of start of treatment protocol or oral antibiotics within 4 weeks of start of protocol treatment.
  10. Patients at significant risk of infection, which in the opinion of the investigator would put the patient at risk to participate in the study (e.g. leg ulceration, indwelling urinary catheter, septic joint within 52 weeks (or ever if prosthetic joint still in situ)).
  11. Patients with known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections including herpes zoster (for tuberculosis and Hepatitis B and C see below), but excluding fungal infections of nail beds as per clinical judgment.
  12. Patients with untreated active current or latent tuberculosis (TB). Patients should have been screened for latent TB (as per BSR guidelines) within 24 weeks prior to the screening visit and, if positive, treated following local practice guidelines prior to the start of protocol treatment.
  13. Patients with active current hepatitis B and/or C infection. Patients should have been screened for hepatitis B and C within 24 weeks prior to the screening visit and if positive, excluded from the study.
  14. Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.
  15. Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use an effective birth control measure (Appendix 2) whilst receiving treatment and after the last dose of protocol treatment as indicated in the relevant SmPC/IB.
  16. Men whose partners are of child-bearing potential but who are unwilling to use an effective birth control measure (Appendix 2) whilst receiving treatment and after the last dose of protocol treatment as indicated in the relevant SmPC/IB.
  17. Patients with known significantly impaired bone marrow function as for example significant anaemia, leukopaenia, neutropaenia or thrombocytopaenia as shown by the following laboratory values at the time of the screening visit:

    • Haemoglobin < 8.5 g/dl
    • Platelet count < 100 x 109 / L
    • White blood cell count < 2.0 x 109 / L
    • Neutrophil count < 1 x 109 / L
  18. Patients with known severe hypoproteinaemia at the time of the screening visit, e.g. in nephrotic syndrome or impaired renal function, as shown by:

    • Serum Creatinine > 150 umol / L
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01295151

Contacts
Contact: Claire Davies 0113 343 0281 ctru_switch@leeds.ac.uk

Locations
United Kingdom
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital Recruiting
Leeds, West Yorkshire, United Kingdom, LS7 4SA
Contact: Maya Buch    0113 392 3043 ext 0044    m.buch@leeds.ac.uk   
Sponsors and Collaborators
Julia Brown
Investigators
Principal Investigator: Maya Buch University of Leeds
  More Information

No publications provided

Responsible Party: Julia Brown, Director of Leeds Institute of Clinical Trials Research, University of Leeds
ClinicalTrials.gov Identifier: NCT01295151     History of Changes
Other Study ID Numbers: RR10/9589, 2010-023880-17
Study First Received: February 11, 2011
Last Updated: March 5, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Rituximab
Abatacept
TNFR-Fc fusion protein
Immunoglobulin Fab Fragments
Infliximab
Adalimumab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents
Immunosuppressive Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Gastrointestinal Agents
Central Nervous System Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on July 24, 2014